Literature DB >> 18505909

Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.

I G C Hermsen1, H Gelderblom, J Kievit, J A Romijn, H R Haak.   

Abstract

OBJECTIVE: Adrenal cortical carcinoma (ACC) is an aggressive tumour with a high mortality. We describe six patients living 12-28 years despite recurrent and/or metastatic ACC. PATIENTS: The first patient presented in 1979 with an ACC of 8 cm. After resection, she developed seven recurrences for which she was treated with resection and/or mitotane (o,p'-DDD) treatment. The patient is still alive 28 years after diagnosis. The second patient presented with an ACC of 9 cm. After resection, the patient developed liver metastases, which were treated with o,p'-DDD. The patient is still alive 25 years after diagnosis. The third patient presented with an ACC of 12 cm. The tumour was resected followed by o,p'-DDD treatment. She had a local recurrence that was completely resected. She is still alive 18 years after diagnosis. The fourth patient presented with an ACC of 14 cm. After resection, adjuvant o,p'-DDD was started. Subsequently, the patient developed two recurrences, which were resected. He is still alive 17 years after the initial diagnosis. The fifth patient presented with an ACC of 10 cm. After diagnosis, she developed lung metastasis, which were treated with o,p'-DDD and chemotherapy. The patient is still alive with slowly progressive disease 12 years after diagnosis. The sixth patient presented with an ACC of 7 cm. After resection, she developed four recurrences, which were resected. The patient is still alive 28 years after diagnosis.
CONCLUSION: Some patients can have an extremely long survival of ACC, despite recurrent disease and metastases. The mainstay of therapy in our patients was repeated surgery and o,p'-DDD.

Entities:  

Mesh:

Year:  2008        PMID: 18505909     DOI: 10.1530/EJE-07-0723

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

1.  Actual 10-year survivors following resection of adrenocortical carcinoma.

Authors:  Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 3.  Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.

Authors:  Michael R Clay; Emilia M Pinto; Lauren Fishbein; Tobias Else; Katja Kiseljak-Vassiliades
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

4.  Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels.

Authors:  Xiaozeng Lin; Yan Gu; Yingying Su; Ying Dong; Pierre Major; Anil Kapoor; Damu Tang
Journal:  Cancers (Basel)       Date:  2022-06-05       Impact factor: 6.575

5.  Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network.

Authors:  M H T Ettaieb; J C Duker; R A Feelders; E P M Corssmit; C W Menke-van der Houven van Oordt; H J L M Timmers; M N Kerstens; J W Wilmink; P M Zelissen; B Havekes; H R Haak
Journal:  Horm Cancer       Date:  2016-07-15       Impact factor: 3.869

6.  Pubertal outcome in a female with virilizing adrenocortical carcinoma.

Authors:  Emily Breidbart; Tamara Cameo; James H Garvin; Hanina Hibshoosh; Sharon E Oberfield
Journal:  J Pediatr Endocrinol Metab       Date:  2016-04       Impact factor: 1.634

7.  Adrenocortical carcinoma: modern management and evolving treatment strategies.

Authors:  Lucas A McDuffie; Rachel D Aufforth
Journal:  Int J Endocr Oncol       Date:  2016-04-08

8.  A case of primary clear cell hepatocellular carcinoma in a non-cirrhotic liver: an immunohistochemical and ultrastructural study.

Authors:  Erica Fan Clayton; Emma Elizabeth Furth; Amy Ziober; Theodore Xu; Yuan Yao; Pil Gyu Hwang; Zhanyong Bing
Journal:  Rare Tumors       Date:  2012-05-17

9.  Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors.

Authors:  Dorothee Heck; Sebastian Wortmann; Luitgard Kraus; Cristina L Ronchi; Richard O Sinnott; Martin Fassnacht; Silviu Sbiera
Journal:  Horm Cancer       Date:  2015-12       Impact factor: 3.869

10.  Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases.

Authors:  Mark J McCabe; Mark Pinese; Chia-Ling Chan; Nisa Sheriff; Tanya J Thompson; John Grady; Marie Wong; Marie-Emilie A Gauthier; Clare Puttick; Velimir Gayevskiy; Elektra Hajdu; Stephen Q Wong; Wade Barrett; Peter Earls; Robyn Lukeis; Yuen Y Cheng; Ruby C Y Lin; David M Thomas; D Neil Watkins; Marcel E Dinger; Ann I McCormack; Mark J Cowley
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.